Logo image of CLDI

CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Fundamental Analysis

NYSEARCA:CLDI - NYSE Arca - US3207033099 - Common Stock - Currency: USD

0.345  +0 (+0.47%)

After market: 0.3301 -0.01 (-4.32%)

Fundamental Rating

1

CLDI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. CLDI may be in some trouble as it scores bad on both profitability and health. CLDI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLDI had negative earnings in the past year.
In the past year CLDI has reported a negative cash flow from operations.
In the past 5 years CLDI always reported negative net income.
CLDI had a negative operating cash flow in each of the past 5 years.
CLDI Yearly Net Income VS EBIT VS OCF VS FCFCLDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -143.22%, CLDI is doing worse than 84.79% of the companies in the same industry.
CLDI has a Return On Equity of -310.83%. This is in the lower half of the industry: CLDI underperforms 72.63% of its industry peers.
Industry RankSector Rank
ROA -143.22%
ROE -310.83%
ROIC N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLDI Yearly ROA, ROE, ROICCLDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLDI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDI Yearly Profit, Operating, Gross MarginsCLDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CLDI has been increased compared to 1 year ago.
Compared to 1 year ago, CLDI has an improved debt to assets ratio.
CLDI Yearly Shares OutstandingCLDI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
CLDI Yearly Total Debt VS Total AssetsCLDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

Based on the Altman-Z score of -14.89, we must say that CLDI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CLDI (-14.89) is worse than 80.32% of its industry peers.
CLDI has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.11, CLDI is doing worse than 65.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -14.89
ROIC/WACCN/A
WACCN/A
CLDI Yearly LT Debt VS Equity VS FCFCLDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

2.3 Liquidity

CLDI has a Current Ratio of 2.12. This indicates that CLDI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.12, CLDI is doing worse than 74.06% of the companies in the same industry.
CLDI has a Quick Ratio of 2.12. This indicates that CLDI is financially healthy and has no problem in meeting its short term obligations.
CLDI has a worse Quick ratio (2.12) than 72.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 2.12
CLDI Yearly Current Assets VS Current LiabilitesCLDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.13% over the past year.
Looking at the last year, CLDI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)63.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.94%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CLDI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.63% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.59%
EPS Next 2Y40%
EPS Next 3Y25.5%
EPS Next 5Y14.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLDI Yearly Revenue VS EstimatesCLDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2029 2030 2031 20M 40M 60M
CLDI Yearly EPS VS EstimatesCLDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLDI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDI Price Earnings VS Forward Price EarningsCLDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDI Per share dataCLDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

CLDI's earnings are expected to grow with 25.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40%
EPS Next 3Y25.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLDI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (6/13/2025, 8:04:02 PM)

After market: 0.3301 -0.01 (-4.32%)

0.345

+0 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-20 2025-05-20
Earnings (Next)N/A N/A
Inst Owners4.05%
Inst Owner Change367.43%
Ins Owners3.62%
Ins Owner Change0.42%
Market Cap10.97M
Analysts85.71
Price Target10.2 (2856.52%)
Short Float %0.91%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)60%
PT rev (3m)60%
EPS NQ rev (1m)45.85%
EPS NQ rev (3m)45.85%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 1.58
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -143.22%
ROE -310.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 2.12
Altman-Z -14.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.94%
EPS Next Y73.59%
EPS Next 2Y40%
EPS Next 3Y25.5%
EPS Next 5Y14.63%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-102.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.2%
OCF growth 3YN/A
OCF growth 5YN/A